Health Care
BD's Q3 FY2026 saw solid revenue growth offset by margin pressure from tariffs and restructuring, while the company completed its Life Sciences spin-off and returned significant capital to shareholders.
Key risk: China Market and Volume-Based Procurement (VBP) Risk
Market dynamics in China, including VBP programs and cost-containment efforts, have adversely impacted BD's revenues, particularly in the Medical Essentials and Interventional segments. The company experienced declines in certain product categories, and this trend could persist if government policies further reduce pricing or demand.
Other Health Care Equipment companies